The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | The use of multi-omics to understand the progression from MGUS to WM
Simone Ferrero, MD, University of Torino and Hospital “Città della Salute e della Scienza di Torino”, Torino, Italy, discusses how multi-omics studies could be used to decipher which patients with monoclonal gammopathy of undetermined significance (MGUS) may progress to Waldenström’s macroglobulinemia (WM). He mentions how the identification of prognostic markers could allow pre-emptive treatment to prevent the transformation of disease. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant: Janssen, EUSA Pharma, Abbvie and Sandoz; Advisory board: Janssen, EUSA Pharma, Recordati, Incyte, Roche, Astra Zeneca and Italfarmaco; Speaker’s honoraria: Janssen, EUSA Pharma, Recordati, Lilly, Beigene, Gilead and Gentili ; Research funding: Gilead, Beigene and Morphosys.
